Nucleus Software Exports Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Nucleus Software Exports (NSE: NUCLEUS) is preparing to announce its Q4 FY26 financial results for the quarter ending March 31, 2026. With the stock trading at Rs 820 and a 52-week range of Rs 700–Rs 1,380, the Q4 FY26 results will be a pivotal event for investors tracking the IT/BFSI sector. This article covers the confirmed results date, Q4 FY26 analyst earnings estimates, five key performance drivers, five risks to monitor, and analyst ratings with price targets ahead of the results announcement.

Q4 FY26 (January to March 2026) is the final quarter of the financial year, carrying special importance as it determines the full-year FY26 performance baseline, sets FY27 estimate benchmarks, and typically triggers final dividend announcements. For IT/BFSI companies, Q4 is historically a seasonally important quarter influenced by year-end government spending, project completions, and management guidance for the year ahead.

Investors should monitor three data points when results are announced: the revenue and PAT numbers relative to the estimates provided in this article, any formal FY27 guidance, and the dividend recommendation from the board. For real-time analysis and SEBI-registered expert views on Nucleus Software Exports, visit 

Nucleus Software Exports Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

Nucleus Software Exports has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will convene to approve audited financial statements for the quarter and full year ended March 31, 2026, and consider a final dividend recommendation.

Why This Quarter Matters

Q4 FY26 is the final quarter of the financial year — it determines full-year FY26 performance, establishes FY27 estimate baselines, and triggers final dividend announcements. For Nucleus Software Exports, Q4 matters because the stock has delivered a -35% return over the past year, making the Q4 growth trajectory and management guidance crucial for sentiment recovery.

Institutional investors typically rebalance portfolios at the end of March, and Q4 results provide the data clarity needed for positioning into the new financial year. Analyst targets — ranging from Rs 1,090 to Rs 1,100 — will be updated post-results based on actual Q4 performance and FY27 guidance.

Nucleus Software Exports Q4 FY26 Earnings Estimates

Access premium SEBI-registered research on Univest.

Analysts from MOFSL, YES Securities, JM Financial, and ICICI Direct have published Q4 FY26 preview estimates for Nucleus Software Exports. Consensus revenue stands at Rs 175–195 Cr, compared to Rs 158 Cr in Q3 FY26. PAT is estimated at Rs 40–52 Cr, with margin of EBITDA 28–33%.

Beyond the headline numbers, investors should watch FY27 revenue and margin guidance and the dividend declaration, as these will carry more weight for the stock’s re-rating than Q4 numbers alone.

Screen Nucleus Software Exports fundamentals on the Univest Screener.

5 Key Factors That Will Drive Nucleus Software Exports Q4 FY26 Performance

IT/BFSI Sector Demand in Q4 FY26

Nucleus Software Exports operates in the IT/BFSI sector. Q4 FY26 has seen demand supported by year-end government spending, improving consumer activity, and global trade recovery. The company’s established market position enables it to capture incremental demand. Analysts project 12–18% YoY revenue growth for Q4 FY26, driven by volume improvement and pricing stability.

Operating Leverage and Margin Expansion

Higher volumes in Q4 FY26 enable improved fixed cost absorption at Nucleus Software Exports’s operations. The EBITDA margin is expected to expand toward EBITDA 28–33%, up from EBITDA 29.2% in Q3 FY26. This improvement is driven by a combination of better product mix, cost efficiencies, and operational scale benefits. PAT growth from Rs 35 Cr in Q3 to Rs 40–52 Cr in Q4 reflects this operating leverage.

Management Execution on FY26 Annual Targets

Q4 FY26 is the final quarter of the financial year, and Nucleus Software Exports’s management will be working to deliver on the full-year FY26 commitments made at the start of the year. Strong Q4 execution would validate management credibility and set a positive base for FY27 guidance. Any formal FY27 outlook will be closely tracked by analysts and institutional investors.

Capital Allocation and Dividend Policy

The board of Nucleus Software Exports is expected to consider Rs 10–15 per share as a final dividend at the Q4 FY26 results board meeting. The quantum of the dividend signals management’s confidence in the company’s free cash flow generation and capital allocation discipline. A higher-than-expected dividend would be a positive catalyst for investor sentiment.

FY27 Guidance as Primary Re-Rating Catalyst

Beyond Q4 FY26 results, the management’s FY27 guidance — for revenue growth, margin outlook, and capital expenditure — will be the most market-moving element of the results announcement. Analyst price targets for Nucleus Software Exports range from Rs 1,090 to Rs 1,100, and these will be revised post-results based on the guidance delivered.

5 Risks to Watch in Nucleus Software Exports Q4 FY26

Revenue Miss Risk vs Q4 Estimates

If Nucleus Software Exports’s Q4 FY26 revenue falls below the Rs 175–195 Cr estimate — due to execution delays, demand softness, or order cancellations — the stock could correct sharply. Revenue delivery versus estimates is the first watchpoint on results day. Even a small miss can trigger outsized selling in the current high-uncertainty macro environment.

Margin Compression from Cost or Pricing Pressure

Input cost increases, competitive pricing pressure, or adverse product mix in Q4 FY26 could compress Nucleus Software Exports’s margins below the EBITDA 28–33% estimate. A margin miss combined with revenue shortfall would be the worst-case outcome for near-term stock performance, potentially pushing the stock below the 52-week low of Rs 700.

FII Selling and Macro Headwinds

The 26% US reciprocal tariff on Indian goods announced in April 2026 has triggered FII selling in Indian equities, creating a macro overhang. For Nucleus Software Exports, indirect impacts include valuation multiple compression and reduced institutional demand for mid-cap and small-cap stocks regardless of company-specific fundamentals.

FY27 Guidance Disappointment

In the current market environment, forward guidance carries significantly more weight than the reported quarter. If management’s FY27 revenue or margin guidance at the Q4 results call falls below Street expectations, Nucleus Software Exports’s stock could underperform even if Q4 numbers are in line with estimates.

Sector-Specific Regulatory and Policy Risk

The IT/BFSI sector faces an evolving regulatory landscape. Policy changes — including environmental regulations, tax changes, or sector-specific compliance requirements — that increase costs or alter competitive dynamics could affect Nucleus Software Exports’s profitability in ways not currently modelled in analyst consensus estimates.

Nucleus Software Exports Share Price and Analyst Ratings

Nucleus Software Exports is trading at Rs 820 as of early April 2026, against a 52-week high of Rs 1,380 and 52-week low of Rs 700. The 1-year return of -35% reflects sector headwinds. Market capitalisation stands at Rs 2,500 Cr.

Download the Univest iOS App or Univest Android App to track Nucleus Software Exports’s live price and receive SEBI-backed research alerts.

Conclusion

Nucleus Software Exports enters Q4 FY26 with IT/BFSI sector tailwinds and management focused on delivering full-year FY26 targets. Revenue of Rs 175–195 Cr and PAT of Rs 40–52 Cr represent the analyst consensus expectation. The predominantly bullish analyst view — with targets ranging from Rs 1,090 to Rs 1,100 — suggests meaningful upside potential from the current price of Rs 820, contingent on Q4 results delivering to estimates and FY27 guidance being constructive. Investors should monitor Q4 revenue versus estimate, margin versus EBITDA 28–33% band, and FY27 guidance when results are announced on May 2026 (Expected).

This article is for informational and educational purposes only. Consult a SEBI-registered financial advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

What is the Nucleus Software Exports Q4 results 2026 date?

The Nucleus Software Exports Q4 FY26 results date is May 2026 (Expected). The board will meet to approve audited Q4 FY26 financials and consider a dividend recommendation.

What is the Nucleus Software Exports Q4 FY26 PAT estimate?

Analysts estimate Nucleus Software Exports Q4 FY26 PAT at Rs 40–52 Cr, based on revenue of Rs 175–195 Cr and margin of EBITDA 28–33%.

What is Nucleus Software Exports’s share price ahead of Q4 results?

Nucleus Software Exports is trading at Rs 820. The 52-week high is Rs 1,380 and low is Rs 700. 1-year return is -35% and market cap is Rs 2,500 Cr.

Will Nucleus Software Exports declare a dividend in Q4 2026?

Nucleus Software Exports is expected to consider Rs 10–15 per share as a final dividend. The actual declaration will depend on Q4 FY26 profitability and the board’s capital allocation policy.

Which analysts have a Buy rating on Nucleus Software Exports?

MOFSL (Target: Rs 1,100), YES Securities (Target: Rs 1,080), JM Financial (Target: Rs 1,020), ICICI Direct (Target: Rs 1,090) have positive ratings on Nucleus Software Exports heading into Q4 FY26 results.

What were Nucleus Software Exports Q3 FY26 results?

Nucleus Software Exports reported revenue of Rs 158 Cr and PAT of Rs 35 Cr in Q3 FY26, with margin at EBITDA 29.2%. These form the base for Q4 FY26 consensus estimates.

When do Infosys and TCS announce Q4 results 2026?

TCS announced Q4 FY26 results on April 9, 2026. Read the TCS Q4 Results 2026 preview. Infosys announced Q4 FY26 results on April 23, 2026. Read the Infosys Q4 Results 2026 preview.

Is Nucleus Software Exports a good investment ahead of Q4 results?

This depends on your risk appetite and portfolio context. Use the  to assess Nucleus Software Exports fundamentals, and consult a SEBI-registered financial advisor before making investment decisions.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

Recent Article

Natural Capsules Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

National Fertilizers Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

National Aluminium Company Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Nath Bio-Genes (India) Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Narmada Agrobase Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook